RT Journal Article
T1 Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
A1 Hontecillas-Prieto, Lourdes
A1 Garcia-Dominguez, Daniel J
A1 Vaca, Diego Pascual
A1 Garcia-Mejias, Rosa
A1 Marcilla, David
A1 Ramirez-Villar, Gema L
A1 Saez, Carmen
A1 de Álava, Enrique
K1 MDR3
K1 MRP1
K1 Wilms tumours
K1 blastemal stratification
K1 multidrug resistance transporters
AB Wilms tumour (WT) is the most common renal tumour in children. Most WT patients respond to chemotherapy, but subsets of tumours develop resistance to chemotherapeutic agents, which is a major obstacle in their successful treatment. Multidrug resistance transporters play a crucial role in the development of resistance in cancer due to the efflux of anticancer agents out of cells. The aim of this study was to explore several human multidrug resistance transporters in 46 WT and 40 non-neoplastic control tissues (normal kidney) from patients selected after chemotherapy treatment SIOP 93-01, SIOP 2001. Our data showed that the majority of the studied multidrug resistance transporters were downregulated or unchanged between tumours and control tissues. However, BCRP1, MDR3 and MRP1 were upregulated in tumours versus control tissues. MDR3 and MRP1 overexpression correlated with high-risk tumours (SIOP classification) (p = 0.0022 and p
YR 2017
FD 2017
LK http://hdl.handle.net/10668/10746
UL http://hdl.handle.net/10668/10746
LA en
DS RISalud
RD Apr 11, 2025